EASD 2025: Impacting Lives of People with Diabetes in Resource Constrained Settings @EASDiabetes

Uploaded October 2025 | Updated September 2026, 3 days ago

According to Dr. Viswanathan Mohan, recipient of the inaugural Diabetes Impact Prize recipient, India is facing a diabetes epidemic of global proportions. In this EASD TV interview, host Vivienne Parry speaks to Dr. Mohan (Madras Diabetes Research Foundation, Chennai), the first recipient of the EASD Global Impact Prize. Dr. Mohan shares insights into the staggering rise of type 2 diabetes across South Asia and the urgent need for prevention and education.

From the role of genetics and diet to the impact of pollution, urbanisation and climate change, Dr. Mohan discusses the multifactorial causes behind the crisis and how research and technology, including CGM adoption and genetic screening, can transform care. He also reflects on 50 years of advancing diabetes medicine in India.

Discover how Dr Mohan’s lifelong mission is shaping the global fight against diabetes and his hope for a future cure.

#EASD2025 #GlobalHealth #DiabetesResearch #Type2Diabetes #India #GlobalImpactPrize

EASD 2025: Impacting Lives of People with Diabetes in Resource Constrained Settings

$Best of EASD 2025 by the EASD Early Career Academy – featuring Dr. Michael Leutner In the seventh episode of our highlights from the EASD Annual Meeting 2025 in Vienna series, Dr. Michael Leutner from the Medical University of Vienna, Austria shares insights from the SOUL Trial which investigated the effects of oral semaglutide on cardiovascular outcomes in people with type 2 diabetes. Michael Leutner explains the design and baseline characteristics of the SOUL Trial and presents the main outcomes regarding heart failure and peripheral artery disease. Main trial outcomes for heart failure include: - Oral semaglutide reduces heart failure events or cardiovascular death in people with type 2 diabetes with a history of heart failure compared to placebo. - Benefits were strongly observed in trial participants with heart failure with preserved ejection fraction (HFpEF), with no safety concerns identified in this group - Positive effects were observed regardless of the high baseline use of SGLT-2 inhibitors or mineralocorticoid receptor antagonists - No increased risk of serious adverse events Main trial outcomes for peripheral artery disease include: - Oral semaglutide reduces major adverse limb events, including acute limb ischemia and chronic limb ischemia #easd2025 #Diabetes #Type2Diabetes #HeartFailure #CardiovascularDisease #ClinicalTrial #DiabetesResearch$

1st EASD Early Career Academy Journal Club - 20 Oct 2022

What’s new in the 2022 ADA/EASD consensus report on the management of hyperglycaemia in T2D?

EASD 2024 - Help! I Need Somebody - Complex Diabetes Cases in the Emergency Room

EASD 2023 - Butheinah Al-Sharafi and Brij Makkar on diabetes care during natural disaster and war

EASD 2023 - Interview with Åke Lernmark, recipient of the Claude Bernard Prize 2023

Meet the EASD Early Career Academy - Introducing: Shivani Misra

5th EASD Early Career Academy Webinar: Real World Evidence in Diabetes Research

#EASD2022 Interview with Dr Adshead & Prof. Heinemann on climate change, environment and diabetes

EASD 2024: Diabetologia Journal in Review: Innovations, AI and the Future of Diabetes Research

EASD 2023 - Interview with Timo Müller, recipient of the Minkowski Prize 2023